Cancer Research Technology
Log in Register
Menu

TAM1 cell line

Invented at University of Illinois, Chicago

Info

Catalogue Number 156373
Antigen/Gene or Protein Targets TAM1
Parental Line MCF-7
Synonyms MCF7
Host Human
Tissue Breast
Disease Keywords Breast Cancer; Tamoxifen Resistance
Model Cancer Model
Relevance Approximately 70% of breast cancer patients have estrogen receptor positive (ER+) tumors. The selective estrogen receptor modulator (SERM), tamoxifen, and aromatase inhibitors (AIs) represent first-line treatment for ER+ patients however, up to 50% of patients either do not respond or acquire resistance within 5 years of treatment. The MCF-7/TAM1 cell line shows an endogenous resistance to tamoxifen. The cells also exhibit an increased expression of Protein Kinase C alpha (PKCĪ±), which is an important player in tamoxifen resistant breast cancer.
Research Area Cancer, Drug Discovery & Development
Notes Engineered to over-express TAM1, which in turn causes over expression of PKCĪ±.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Xiong et al. 2017. J Med Chem. 60(4):1325-1342. PMID: 28117994.


Add a reference

References: 1 entry

Xiong et al. 2017. J Med Chem. 60(4):1325-1342. PMID: 28117994.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor